TickerGuard
Buy Day today: Poor (44) Weak market breadth · major macro event coming up
CDXS

Codexis Inc

Healthcare · Biotechnology

1.40$ -0.7% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement CDXS
Line item 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
14.9% 32.8% 26.1% 20.1% 26.1% 33.7% 34.7% 45.6% 27.5% 15.8% 20.0% 28.6% 20.8% 22.8% 19.9% 21.2% 27.4% 18.3% 27.4% 13.3%
85.1% 67.2% 73.9% 79.9% 73.9% 66.3% 65.3% 54.4% 72.5% 84.2% 80.0% 71.4% 79.2% 77.2% 80.1% 78.8% 72.6% 81.7% 72.6% 86.7%
142.3% 140.7% 90.2% 66.0% 48.9% 49.3% 64.3% 99.0% 64.4% 49.5% 45.5% 59.3% 49.5% 49.5% 64.0% 53.4% 57.8% 83.9% 78.0% 74.3%
98.0% 77.8% 70.7% 36.0% 31.6% 29.8% 35.5% 82.7% 62.1% 53.4% 52.0% 58.0% 48.3% 46.0% 50.8% 47.1% 37.4% 75.5% 92.9% 66.9%
240.3% 218.5% 161.0% 102.0% 80.5% 79.1% 99.8% 183.3% 126.6% 102.8% 97.6% 117.3% 97.8% 95.5% 114.7% 100.5% 97.7% 178.8% 171.2% 141.2%
-155.2% -151.4% -87.1% -22.2% -6.7% -12.8% -34.6% -128.9% -54.1% -18.6% -17.5% -45.9% -18.6% -18.3% -34.6% -21.7% -25.2% -97.0% -98.6% -54.5%
6.0% 10.0% 4.7% 2.5% 0.5% 0.5% 0.3% 1.0% 0.1% 0.0% 0.1% 0.3% 1.1% 7.6% 7.0% 7.2% 1.0% 17.5% 17.5% 6.8%
-155.0% -155.5% -88.8% -24.4% -7.6% -13.2% -34.6% -129.7% -54.7% -18.9% -17.6% -45.8% -18.0% -17.4% -34.3% -20.1% -24.0% -108.6% -109.9% -62.4%
-1.0% -1.6% 0.6% 0.1% 0.4% 0.2% 0.3% -0.3% -0.7% -0.8% -0.1% 0.2% -0.1% 0.0% 0.5% 0.2% 0.2% 0.1% 0.1% 0.1%
-154.0% -153.9% -89.4% -24.5% -8.0% -13.4% -34.9% -129.4% -54.0% -18.1% -17.5% -46.0% -18.0% -17.4% -34.8% -20.3% -24.2% -108.7% -110.0% -62.5%
-129.4% -140.0% -75.0% -14.5% 0.6% -3.9% -20.5% -97.3% -35.2% -5.6% -8.2% -43.8% -16.7% -11.7% -28.0% -16.0% -19.0% -70.3% -90.0% -48.1%

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?